The neuropeptide Y Y 5 receptor subtype has generated great interest, especially regarding its possible involvement in feeding behaviors. However, its distribution and sites of expression in the mammalian brain are, in large part, unknown because of the lack of selective tools. We demonstrate in this study that spe- sites in the rat brain, with the external plexiform layer of the olfactory bulb, the lateral septum, the anteroventral thalamic nucleus, the CA3 subfield of the ventral hippocampus, the nucleus tractus solitarius, and the area postrema being most enriched. Rather surprisingly, in the hypothalamus, a key structure modulating food intake, only low densities of Y 5 binding sites were detected as well as in most other regions of the rat brain. These data suggest that the Y 5 receptor protein is expressed and translated by a small percentage of hypothalamic neurons and that the effect of NPY on feeding behaviors likely is mediated by more than one class of NPY receptors. It also indicates that the Y 5 receptor may be involved in other biological actions induced by NPY. Taken together, these data represent the first pharmacological demonstration of the expression and discrete localization of the Y 5 receptor protein in the rat brain.
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Neuropeptide Y (N PY) is a 36-amino-acid peptide that shares high sequence homology with peptide YY (PYY) and the pancreatic polypeptides (PPs) (Tatemoto et al., 1982) . N PY is one of the most abundant peptides found in the mammalian brain (Chronwall et al., 1985; DeQuidt and Emson, 1986a,b) . Intracerebroventricular injections, as well as direct administration into specific nuclei, of N PY/ PYY fragments and analogs induce several biological responses, including increased food intake, modulation of luteinizing hormone-releasing hormone (L HRH) and corticotropin-releasing factor (CRF) releases, regulation of cardiorespiratory parameters, enhanced cognitive f unction associated with learning and memory, shifts of circadian rhythms, and reduction of anxiety-related behaviors (Dumont et al., 1992; Kalra and Crowley, 1992; Grundemar et al., 1993; Wahlestedt and Reis, 1993; Heilig and Widerlov, 1995; Munglani et al., 1996) . Additionally, studies in rodents suggest that N PY and its receptors could have a direct implication in some pathological disorders, including obesity, depression, and epilepsy (Wahlestedt and Reis, 1993; Colmers and Bleakman, 1994; Munglani et al., 1996; Klapstein and Colmers, 1997) .
The various biological effects of N PY and homologs are mediated by the activation of at least five classes of receptors termed Y 1 , Y 2 , Y 4 , Y 5 , and Y 6 (Dumont et al., 1992; Wahlestedt and Reis, 1993; Colmers and Bleakman, 1994; Gehlert, 1994; Blomqvist and Herzog, 1997; Michel et al., 1998) , all of which have been cloned (Eva et al., 1990; Herzog et al., 1992; Larhammar et al., 1992; Bard et al., 1995; Gerald et al., 1995 Gerald et al., , 1996 Lundell et al., 1995; Rose et al., 1995; Weinberg et al., 1996) . The pharmacology of each of these receptor subtypes has been defined by using several analogs and fragments of NPY, PYY, and PPs (for more details, see Michel et al., 1998) .
Moreover, the recent development of the Y 1 nonpeptide antagonists BIBP3226 (Rudolf et al., 1994) and SR 120819A (Serradeil-Le Gal et al., 1995) as well as a Y 1 peptidergic antagonist, 1229U91 [Daniels et al. (1995) ; now known as GW1229; Bitran et al. (1997) ], helps to improve our understanding of the role of this receptor subtype in mediating some of the effects of NPY. BIBP3226 has been studied most extensively and has been shown to behave as a competitive, selective, and specific Y 1 receptor antagonist in various binding assays and in in vitro and in vivo bioassays (Rudolf et al., 1994; Abounader et al., 1995; Doods et al., 1995; Jacques et al., 1995; Wieland et al., 1995; Lundberg et al., 1996) without any significant activity at the Y 2 (Rudolf et al., 1994; Jacques et al., 1995) , Y 4 (Gehlert et al., 1996a,b; Gerald et al., 1996) , and Y 5 (Gerald et al., 1996) (Dumont et al., , 1996a Jacques et al., 1997 (Dumont et al., 1996b (Bard et al., 1995; Gehlert et al., 1996a,b 
Data represent the mean Ϯ SEM of three to eight determinations. All binding curves were fit to a one-or a two-binding sites model by a nonlinear method of analysis, using GraphPad Prism Software competition data analysis. The goodness of fit between the two models was tested by F test (p ϭ 0.05). K H and K L represent the affinity of competitors for the high-and low-affinity sites, respectively. IC 50 represents the concentration of competitors needed to inhibit 50% of the specific binding. n represents the Hill coefficient.
high affinities for human PP (hPP), but not rat PP (rPP), with a competition binding profile similar to that of the cloned Y 5 receptor subtype (Gerald et al., 1996) . Moreover, this Y 5 -like receptor subtype is distributed very discretely in the rat brain, with highest levels seen in the external plexiform layer of the olfactory bulb, the lateral septum, the anteroventral thalamic nucleus, the CA3 subfield of the ventral hippocampus, the nucleus tractus solitarius, and the area postrema. Rather unexpectedly, however, various hypothalamic nuclei are not enriched with specific binding, raising issues as to its critical role in feeding behaviors.
MATERIALS AND METHODS
Materials. Male Sprague Dawley CD rats (200 -250 gm) obtained from Charles River C anada (St. Constant, Québec, C anada) were kept on a 12 hr light /dark cycle (light on at 7:00 A.M.) in temperature-and humiditycontrolled rooms. Animals were fed with standard laboratory chow and had access to tap water ad libitum. Animal care was given according to protocols and guidelines approved by McGill University and the C anadian Council of Animal C are.
Analogs and fragments of PYY and pN PY were synthesized in our laboratories as previously described (Forest et al., 1990) ; avian PP (aPP), bovine PP (bPP), rPP, hPP, and ]N PY were purchased from Bachem C alifornia (Torrance, CA) and Peninsula Laboratories (Belmont, CA). BI BP3226 and BI BP3435 were generously provided by Karl Thomae GmbH (Germany); GW1229 was a gift from Glaxo Wellcome (Research Triangle Park, NC). Bovine serum albumin (BSA) and iodine-125 were obtained from IC N Biochemicals C anada (Montréal, Québec, C anada), and bacitracin was purchased from Sigma (St. L ouis, MO). Schleicher & Schuell #32 glass filters were obtained from Xymotech (Montréal, Québec, C anada). [
3 H]Hyperfilms and 125 I-microscale standards were purchased from Amersham (Mississauga, Ontario, C anada). All other chemicals were of analytical grade and obtained from Fisher Scientific (Montréal, Québec, C anada) or Sigma.
Iodine-125 was incorporated into the tyrosine residue of [Leu 31 ,Pro 34 ]PYY and PYY , using the chloramine T method as previously described , and the specific activity was assumed to be of the theoretical value (2000 C i /mmol).
Membrane binding assays. Membranes were prepared as previously described . Briefly, rats were decapitated and their brains rapidly removed and homogenized in a Krebs'-Ringer's phosphate (K RP) buffer at pH 7.4 of the following composition (in mM): NaC l (120), KC l (4.7), C aC l 2 (2.2), K H 2 PO 4 (1.2), MgSO 4 (1.2), dextrose (5.5), and NaHC O 3 (25), using a Brinkman polytron (at setting 6 for 15-20 sec). Homogenates were centrif uged at 49,000 ϫ g for 20 min; supernatants were discarded, and pellets were washed, resuspended, and recentrif uged twice.
All binding assays were initiated by adding 100 l of membrane preparations in a final volume of 500 l of K RP containing 0.1% (w/ v) BSA, 0.05% (w/ v) Ϫ12 to 10 Ϫ6 M. All binding assays were done in the absence or presence of 1 M BI BP3226 to block the Y 1 receptor subtype (see Results). Nonspecific binding was determined in the presence of 1 M pN PY. After 2 hr the binding reaction was terminated by rapid filtration through Schleicher & Schuell #32 glass filters (previously soaked in 1.0% polyethyleneimine), using a cell harvester filtering apparatus (Brandel Instruments, Gaithersburg, MD). Filters were rinsed three times with 3 ml of cold K RP, and the radioactivity remaining on filters was quantified by using a gamma counter with 85% efficiency (Packard Instruments, Meridian, C T).
All binding experiments were repeated three to six times, each in triplicate, and the results were expressed as a percentage of specific binding representing the mean Ϯ SEM. IC 50 values (i.e., the concentration of unlabeled peptide required to compete for 50% of specific binding of the radioligand) of the various peptides and BI BP3226 were calculated from the competition binding assays data, using the GraphPad Prism (GraphPad Software, San Diego, CA).
Quantitative receptor autoradiography. Receptor autoradiography was performed as described in detail elsewhere (Dumont et al., 1993 (Dumont et al., , 1996a . Briefly, rats were decapitated and their brains rapidly removed from the skull, frozen in 2-methylbutane at Ϫ40°C for 15 sec, and then kept at Ϫ80°C until needed. Sections (20 m) were obtained with a cryomicrotome at Ϫ17°C, mounted on gelatin -chrome -alum-coated slides, dried overnight in a desiccator at 4°C, and then kept at Ϫ80°C until use.
On the days of the experiments, adjacent coronal sections were preincubated for 60 min at room temperature in a K RP buffer at pH 7.4 and then incubated for 120 min in a fresh preparation of K RP buffer con- Ϫ10 to 10 Ϫ5 M). After a 2 hr incubation, sections were washed four times for 2 min each in ice-cold K RP buffer, then dipped in deionized water to remove salts, and rapidly dried. Nonspecific binding was determined by using 1 M N PY for both radioligands. Incubated sections were apposed against 3 H-Hyperfilms for 6 d alongside radioactive standards. Films were developed and quantified as described in detail elsewhere (Dumont et al., 1996a) .
RESULTS
Membrane binding assays in rat brain homogenates revealed that the nonpeptide Y 1 antagonist BI BP3226 (Rudolf et al., 1994) (Fig. 1) . In fact, competition curves were best fit to a two-site model ( p Ͻ 0.05) with high-affinity (K H 1.2 Ϯ 0.3 nM) and low-affinity (K L Ͼ 1000 nM) components ( , as shown in Figure 1 (Gerald et al., 1996) , was Data represent the mean Ϯ SEM of four to nine determinations. n represents the Hill coefficient. IC 50 represents the concentration of competitors needed to inhibit 50% of the specific binding. K H and K L represent, respectively, the affinity of competitors for the high-and low-affinity sites as determined by using a two-binding sites model. , rPP, and GW1229 (Ͼ300 nM) (Fig. 2, Table  2 ). This pharmacological profile is similar to the one reported by Gerald and collaborators (1996) (Dumont et al., 1996a (Fig. 3A-C) , the olfactory nuclei, tenia tecta, olfactory tubercle (Fig. 3A) , claustrum (Fig. 3A,B) , and most thalamic nuclei (Fig. 3B) (Fig. 3B) , geniculate and medial mamillary nuclei, inferior colliculus, tegmental areas (Fig. 3C) , cerebellum, basilar artery, vestibular nuclei, and inferior olive (Fig. 3D) (Fig.  3A) , the lateral septum, the anteroventral nucleus of the thalamus (Fig. 3B) , the CA3 subfield of the ventral hippocampus (Fig. 3C) , the nucleus tractus solitarius, and the area postrema (Fig. 3D) is apparently rather insensitive to BIBP3226 even at concentrations up to 10 M.
A quantitative autoradiographic analysis of these data confirmed that certain regions of the rat brain are resistant to BIBP3226. For example, in the external plexiform layer of the (Fig. 4) . Additionally, the lateral septum, the ventral hippocampus, the nucleus tractus solitarius, and the area postrema also contain significant amounts (Fig. 4) (Trinh et al., 1996; Widdowson, 1997; Widdowson et al., 1997 (Gerald et al., 1996; Hu et al., 1996) (but see above). Moreover, these sites are distributed in a manner strikingly distinct from those reported earlier for the better characterized Y 1 and Y 2 receptors (Dumont et al., 1990 (Dumont et al., , 1993 (Dumont et al., , 1996a Aicher et al., 1991; Gehlert et al., 1992; Larsen et al., 1993) . Rather surprisingly, however, very low densities of these Y 5 -like binding sites are expressed in the hypothalamus, a key structure involved in N PY-mediated effects on feeding behaviors.
Studies (Dumont et al., 1990 (Dumont et al., , 1993 Aicher, 1991; Gehlert et al., 1992; Larsen et al., 1993 (Dumont et al., , 1996a Jacques et al., 1997 binding sites have suggested further heterogeneity of the sites recognized by these probes (Dumont et al., , 1996b Gehlert et al., 1996b) .
In contrast to most peptidergic molecules, BIBP3226 was able to compete, in a clearly biphasic manner, for 65-70% of specific (Rudolf et al., 1994; Doods et al., 1995; Jacques et al., 1995; Wieland et al., 1995) and in neuroblastoma cell lines expressing the Y 1 or the Y 2 receptor subtype (Rudolf et al., 1994; Wieland et al., 1995) . It also is supported by data obtained in a variety of functional in vitro and in vivo bioassays (see introductory remarks). Moreover, in cells transfected with the Y 2 , Y 4 , or Y 5 receptor subtype, BIBP3226 failed to antagonize the effects of NPY on cAMP accumulation or to compete for [ 125 I]PYY binding sites (Gehlert et al., 1996a; Gerald et al., 1996) . It is thus evident that BIBP3226 is a highly selective Y 1 receptor antagonist. In the present study the high affinity of BIBP3226 (5 nM (Rudolf et al., 1994; Wieland et al., 1995) or directly evaluated by using [ 3 H]BIBP3226 . As expected, the S-enantiomer BIBP3435 was inactive in the Y 1 , Y 2 , and Y 5 binding assays present study) .
The purported Y 1 peptide antagonist GW1229 (Daniels et al., 1995; Bitran et al., 1997 ) revealed a competition binding profile Table 2 ) and results reported for the cloned Y 5 receptor subtype expressed in HEK 293 cells and assessed for cAMP production (Gerald et al., 1996) . that was also best fit to a two-site model with high-affinity (0.3 nM) and low-affinity (190 nM) (Gehlert et al., 1996a,b (Trinh et al., 1996) or [ 125 I]bPP Whitcomb et al., 1997) (Bard et al., 1995; Gregor et al., 1996; Lundell et al., 1995; Gehlert et al., 1996a; Gerald et al., 1996) ]PYY binding sites, we performed a series of experiments in the presence of a saturating concentration (1 M) of BIBP3226. Under such experimental conditions, hPP demonstrated the highest affinity, whereas rPP and aPP were much weaker. This is a key characteristic of the recently cloned Y 5 receptor (Gerald et al., 1996; Hu et al., 1996) . Moreover, the long C-terminal fragments NPY 2-36 and PYY ]PYY sites, whereas shorter fragments such NPY , and PYY 13-36 did not, again this being similar to the ligand selectivity profile of the cloned Y 5 receptor expressed in HEK 293 (Gerald et al., 1995) or COS7 (Hu et al., 1996) cell lines. Additionally, the analog ]NPY demonstrated similar affinities (45 and 100 nM) in the Y 5 -transfected cells (Gerald et al., 1996) and in our preparation. Moreover, the affinity of GW1229 to compete against [ ]PYY/BIBP3226-insensitive sites is similar to that reported for the cloned Y 5 receptor subtype (Schober et al., 1998) . In fact, a highly positive correlation (r ϭ 0.89; p Ͻ 0.001) is found between the ligand selectivity profile of the cloned and transfected Y 5 receptor (Gerald et al., 1996) (Stanley et al., 1984 (Stanley et al., , 1993 , and the Y 5 receptor has been proposed to be the "food intake" receptor subtype (Gerald et al., 1996; Hu et al., 1996) ; an in situ hybridization study that used an oligoprobe revealed abundant NPY Y 5 mRNA signals in this area (Gerald et al., 1996) , whereas Y 5 receptor antisense oligonucleotide-treated rats had reduced appetite (Schaffhauser et al., 1997) . Additionally, CGP 71683A, a putative Y 5 antagonist, was able to block significantly the effect of NPY on food intake (Hofbauer et al., 1997) . Taken together, these results support the hypothesis that the Y 5 receptor subtype mediates NPY-induced food intake. In that context it is rather surprising that significant levels of [ 125 I][Leu 31 ,Pro 34 ]PYY/BIBP3226-insensitive sites were not detected in various nuclei of the hypothalamus, including the paraventricular and perifornical nuclei. This apparent discrepancy may be related to (1) a low efficiency in the translation of the Y 5 mRNA into its protein; (2) the fact that only a small proportion of hypothalamic neurons indeed expresses and translates the Y 5 message into its related protein, a higher resolution technique (electron microscopy) being required to visualize properly the binding signals; and (3) the fact that NPY levels in the hypothalamus are very high. Hence, on neuronal stimulation, high amounts of NPY are released and are sufficient to saturate the low levels of receptors available to elicit a full functional response. This hypothesis is supported by the fact that only low levels of Y 1 , Y 2 (Inui et al., 1989; Lynch et al., 1989; Dumont et al., 1990 Dumont et al., , 1993 Martel et al., 1990; Aicher, 1991; Gehlert et al., 1992; Larsen et al., 1993) , and now Y 5 (this study) receptors apparently are expressed in the hypothalamus, even if this brain structure is involved in many NPY-related effects (for review, see Dumont et al., 1992; Kalra and Crowley, 1992; Wahlestedt and Reis, 1993; Heilig and Widerlov, 1995; Munglani et al., 1996) . Finally, (4) the translated Y 5 receptor protein may be located on terminals of projection neurons originating from hypothalamic nuclei. Further investigations that use high-resolution anatomical methods and Y 5 receptor antibodies (not available yet) will be required to verify these various possibilities.
Alternatively, it may be that the Y 5 receptor subtype is not involved uniquely in food intake behaviors or does act via nonhypothalamic structures to modulate appetite. Already, several recent studies have questioned the role of the Y 5 receptor in food intake. For example, Small et al. (1997) reported that the purported Y 5 agonist ]NPY was unable to stimulate food intake while being effective to facilitate adrenocorticotropic hormone release. Moreover, L-152804, a molecule reported to act as an orally active Y 5 antagonist, failed to block normal or NPYinduced feeding behaviors in rodents (Kanatani et al., 1997) . In contrast, numerous laboratories recently have suggested the involvement of the Y 1 receptor subtype in NPY-induced feeding behaviors, mostly on the basis of data obtained with antagonists such as BIBP3226, BIBO3304, GW1229, GI264879, and LY353485 (Kanatani et al., 1996; Daniels et al., 1997; Doods et al., 1997; Iyengar et al., 1997; Kalra, 1997; Li et al., 1997) (but see Gerald et al., 1996; Haynes et al., 1997) . In fact, it well may be that the potent action of NPY and congeners on appetite involved at least two classes of NPY receptors, namely the Y 1 and Y 5 subtypes. Additional yet-to-be-characterized fully NPY-related receptors also may be implicated, as suggested by a few recent anatomical (Trinh et al., 1996) and behavioral studies. Further investigations that use series of potent and fully selective agonists and antagonists (not yet available in most cases) will be necessary to establish fully the role of each receptor subtype in mediating the effects of NPY on food intake.
In summary, our results demonstrate the presence and discrete 
